Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments

Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x.

Abstract

Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Protocols
  • Biomarkers, Tumor / analysis*
  • Brain Neoplasms / chemistry*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / therapy*
  • Clinical Trials as Topic / methods*
  • Humans
  • Molecular Biology / methods*
  • Precision Medicine / methods*
  • Research Design

Substances

  • Biomarkers, Tumor